Offices of Podiatrists (U.S.) — NAICS 621391

An investor's primer. Plain language, dual-audience: relevant to both public-market and private investors.

1. Overview

Podiatrists are foot-and-ankle doctors. This industry — North American Industry Classification System (NAICS) code 621391 — is the network of clinics where a Doctor of Podiatric Medicine (DPM) independently diagnoses and treats bunions, heel pain, ingrown and fungal toenails, sports injuries, and, most consequentially, the foot complications of diabetes.[5][8] It is a classic fragmented, insurance-plus-cash outpatient service business: thousands of small owner-operated offices, no dominant chain, and steady demand tied to an aging, increasingly diabetic population.[5][20]

The industry matters to investors for two reasons: it is a demographically tailwinded, relatively recession-resilient slice of health care, and it has recently become a private-equity roll-up target. The economics are attractive precisely because the market is so scattered — buy up small practices, centralize billing and back-office functions, add ancillary revenue, and sell a larger group.[20][21]

The two ways in are asymmetric:

• Public markets: there is no pure-play publicly traded operator of podiatry offices, and no listed company reports NAICS 621391 as its primary business. Public exposure is indirect — through the device, wound-care, physician-enablement, and health-plan companies that sell to, serve, or pay podiatrists (see Section 4).
• Private markets: this is where ownership actually changes hands. Owning or backing a podiatry group — directly, or through a private-equity-backed management platform — is the primary way to own the industry itself.[20][21][22]

Our view: direct practice ownership offers durable local demand, but returns depend heavily on physician retention, payer contracts, revenue-cycle execution, and regulatory compliance — not on broad industry-wide volume growth.

2. What it is and how it's structured

Scope. NAICS 621391 covers establishments of health practitioners holding a DPM degree who are primarily engaged in the independent practice of podiatry — private or group offices, plus podiatry clinics.[8] Care spans routine and preventive foot care, diabetic-foot examinations and wound care, orthotics (custom shoe inserts) and therapeutic footwear, sports injuries and biomechanics, in-office procedures, and — for surgically trained DPMs — bunion, hammertoe, fracture, deformity, and reconstructive surgery performed in hospitals or ambulatory surgery centers (ASCs).[5][8]

The DPM. A podiatrist is not an MD (Doctor of Medicine) or DO (Doctor of Osteopathic Medicine) but is a separately licensed physician of the foot and ankle. Training is four years of undergraduate study, four years at one of nine accredited U.S. colleges of podiatric medicine, and a three-year hospital-based Podiatric Medicine and Surgery Residency (PMSR).[6] Scope of practice and surgical authority are set state by state; the upper anatomical boundary (ankle versus leg) and amputation limits vary, which materially affects how much surgical revenue a DPM can capture.[7]

What it excludes (and where that care is counted instead):

• Orthopedic foot-and-ankle surgeons who are MDs/DOs bill under 621111 (Offices of Physicians), not here — a direct competitor for surgical cases.[5]
• Physical and occupational therapists — 621340.
• Freestanding ambulatory surgical centers where foot surgery is performed — 621493; hospitals — 622110.
• Orthotics, braces, and therapeutic-shoe manufacturers — 339113 (Surgical Appliance and Supplies Manufacturing).
• Other miscellaneous independent health practitioners — 621399.

A business may operate across several of these categories, but classification follows its primary activity.[8]

Ownership mix. Overwhelmingly small, clinician-owned professional practices — solo DPMs and small groups dominate; about 96% of U.S. podiatry practices have five or fewer physicians.[20] A newer layer sits on top: private-equity-backed management services organizations (MSOs). Under this structure a physician-owned professional entity provides clinical care, an MSO supplies billing, human resources, technology, purchasing, marketing, and recruiting under a management services agreement (MSA), and a private-equity (PE) sponsor owns the MSO or provides growth capital while physicians retain clinical authority where state law requires it.[20][21] The federal data does not publish an ownership split, so this is a qualitative description of a market that also includes solo practices, physician-owned groups, and hospital-affiliated practices.

3. How big it is

Federal business statistics below cover the employer side of the industry (offices with paid staff). Reference years differ, so 2022 receipts should not be read against 2023 payroll as a margin.

For context on the workforce itself: the American Podiatric Medical Association (APMA) and industry M&A sources put the number of U.S. podiatrists at roughly 18,000,[7][20] while the Bureau of Labor Statistics (BLS) counts about 9,700 podiatrist jobs and a median podiatrist wage of $152,800 (May 2024).[5]

The undercount caveat — read this before trusting any single number. The three counts above (≈18,000 podiatrists vs. ≈9,700 jobs vs. 35,977 employees) are not contradictions; they measure different things, and the federal business figures understate total spending on podiatric care:

• CBP and the Economic Census primarily count establishments with paid employees (CBP also excludes most government employees). Solo self-employed DPMs operating as nonemployer businesses are largely excluded, and BLS's ~9,700 job count misses many self-employed practitioners.[42][43] Because NAICS 621391 expressly includes independent private offices, the employer-only figures are best read as a floor.
• Podiatric care delivered inside multispecialty physician groups, hospitals, and surgery centers is counted under 621111, 622110, or 621493 — not here.[5]
• The 35,977 "employees" figure is total staff at podiatry offices (medical assistants, front desk, technicians), not a count of doctors.[1]

Our ground-truth file contains no code-specific nonemployer total, so no adjusted market size is invented. The ~$5.4 billion receipts figure is a floor for office-based podiatry revenue, not the full economic footprint of foot-and-ankle care — which, once hospital surgery, MD-provided foot care, devices, and wound biologics are added, runs to many billions more.[15]

4. The investable universe

Public plays: indirect only

There is no publicly listed company whose business is operating podiatry offices. Public-market investors gain exposure through the suppliers, enablers, and payers of the industry. None of these is a clean proxy for NAICS 621391 — each is a diversified company for which podiatry is one channel among many. Tickers, share prices, and valuation multiples are relevant only for these names, not for the offices themselves.

Private / other owners: where the industry actually trades

The meaningful ownership consolidation is happening in private markets through PE-backed platforms and physician-led groups. Note that a platform's advertised clinic and provider counts are not NAICS 621391 counts — these groups often also include orthopedic surgeons, physical therapists, vascular specialists, wound centers, and research operations.

• U.S. Foot & Ankle Specialists (USFAS) — an NMS Capital portfolio company; advertises 80+ affiliated brands, 200+ locations across 22 states, and 333+ doctors.[22][23]
• Upperline Health — a lower-extremity and multispecialty value-based-care platform (podiatry, endocrinology, primary care) backed by Silversmith Capital Partners and others; announced $58.35 million of new capital in 2023 from Crestline Investors, Silversmith, and additional investors. Current ownership is not fully disclosed in public materials.[24][25]
• Podiatry Growth Partners — a practice-management platform; disclosed financial sponsors include Compass Group Equity Partners, VSS Capital Partners, Siguler Guff, and SunGate Capital.[26][27]
• Balance Health / Weil Foot & Ankle Institute — a majority physician-owned lower-extremity organization formed through merger, combining podiatry with orthopedics, physical therapy, wound care, research, and ancillary services.[28]
• Extremity Healthcare / Village Podiatry — a long-running podiatry practice-management and operating platform; current financial sponsors are not clearly disclosed publicly.[29]

Additional backers active in the space include Shore Capital, Albaron Partners, and others, with add-on deals continuing through 2024–2025.[20][21] For a private investor, the routes are: buy or build an individual practice, invest in or co-invest alongside one of these MSO platforms, or provide the real estate, equipment, or acquisition financing around them.

5. How the money works

Podiatry is a service business with a product tail. Owners make money on three stacked revenue streams:

1. Professional (physician) fees — office visits and in-office procedures billed to Medicare, Medicare Advantage, commercial insurers, and Medicaid, plus some cash pay. Per-visit professional fees are modest — roughly $140–$180 for a routine office visit before ancillaries (practitioner-reported and indicative; the federal data does not publish per-visit revenue). The lever is volume and payer mix: more visits per provider per day, and a healthier commercial-versus-Medicaid mix, drive the top line.
2. Ancillary / in-office revenue — often the margin engine. Custom orthotics, durable medical equipment (DME) such as braces and diabetic therapeutic shoes, in-office imaging, and advanced wound-care biologics (skin substitutes for DFUs) are dispensed at a markup and can materially lift revenue per patient.[5][15]
3. Surgical fees — for surgically trained DPMs, bunion and reconstructive cases (done in hospitals or ASCs) command far higher payments than office visits and are the biggest per-case earners.[5]

Main expenses: DPM and clinical-staff compensation, rent and clinic occupancy, medical supplies and implants, orthotics/footwear costs, malpractice insurance, billing and collections, electronic health record (EHR) systems and technology, and marketing/recruiting/administration. A basic office is not capital-intensive; capital needs rise materially when a platform adds an ASC, imaging, or an orthotics lab.

The metrics that matter for this industry:

• Payer mix (share of Medicare / Medicaid / commercial) — the single biggest driver of revenue per visit, because Medicare rates are fixed and Medicaid is generally lower.[9]
• Provider productivity — visits and collections per DPM per day, schedule fill rate, cancellations and no-shows.
• Ancillary attach rate — orthotics, DME, and wound biologics per patient.
• Surgical case mix — the presence and volume of higher-paying surgery.
• Revenue-cycle health — denial rate and days in accounts receivable.
• Overhead ratio — staff, rent, billing; the whole PE thesis is that centralizing billing and purchasing cuts overhead across many small offices.[21]
• Value-based outcomes — ulcer healing, limb preservation, avoidable hospitalizations, where risk contracts apply.

Federal data does not publish practice-level margins, per-firm revenue, utilization, payer mix, same-clinic growth, or operating cash flow for 621391, so profitability figures come from industry and compensation sources rather than the Census; treat those as estimates.[1][5] Our assessment: chronic diabetic and senior foot care is relatively resilient, while elective surgery, orthotics, and some sports care are more deferrable — labor availability and reimbursement matter more than broad economic cyclicality.

6. What drives demand

Demand is demographic and clinical, which is why it is steady rather than cyclical:

• Aging population. The 2020 Census counted 55.8 million Americans age 65 and older (16.8% of the population).[14] Older feet need more care — mobility, deformity, wound management, and fall-risk reduction. BLS names population aging as a primary demand driver.[5]
• Diabetes and obesity — the dominant structural tailwind. The Centers for Disease Control and Prevention (CDC) estimated 38.4 million people (11.6% of the U.S. population) had diabetes.[13] Rising diabetes prevalence drives peripheral neuropathy and diabetic foot ulcers (DFUs) — the highest-value, highest-stakes podiatric work. The North American DFU-treatment market alone was about $2.8 billion in 2024, and a major (below- or above-knee) amputation can cost the health system over $70,000 — which is exactly why payers fund preventive podiatry.[15]
• Chronic-disease management. Podiatrists are an access point for diabetic-foot prevention, therapeutic footwear, and coordination with primary-care and vascular providers.
• Activity and sports injuries across all ages — more deferrable and referral-sensitive than chronic care.
• Value-based care. Because podiatry can prevent wounds, infections, hospitalizations, and amputations, it creates opportunities for risk-bearing specialty platforms — but it also shifts the business toward documentation, outcomes, and payer integration.[25]
• Succession and administrative pressure. Independent DPMs increasingly face billing complexity, technology costs, and retirement transitions — pressures that create acquisition opportunities for MSOs.[20]

Headwind on the demand side: BLS projects only 2% podiatrist employment growth from 2024 to 2034 (slower than average), partly because primary-care physicians and other clinicians can absorb some routine foot care.[5] The volume of need is rising, but some of it leaks to non-podiatrists.

7. Regulation

Podiatry is heavily shaped by government payers and state licensing:

• Licensing and scope of practice are set by each state's podiatric medical board. Scope generally covers the foot and ankle; the upper boundary and amputation limits vary by state — a material factor in surgical revenue.[7]
• Medicare (CMS) reimbursement is the demand-and-cash-flow linchpin. Medicare excludes most "routine foot care" (nail trimming, callus/corn removal) — except when the patient has a qualifying systemic condition such as diabetes or peripheral vascular disease, in which case it is covered subject to strict documentation, the Q7/Q8/Q9 billing modifiers, and a roughly 60-day frequency limit.[9][10] Separately, Medicare Part B covers therapeutic shoes and inserts for qualifying diabetic patients — generally one pair of depth shoes with three pairs of inserts, or one pair of custom-molded shoes with two additional pairs, subject to documentation and fitting rules.[12] These rules shape a large share of what a podiatry practice can bill.
• Billing and compliance risk is real. CMS reports an 11.2% improper-payment rate for podiatry care on 2024 fee-for-service data, an estimated $216.9 million, driven mainly by insufficient documentation (improper payment is not the same as fraud).[9] A 2025 HHS Office of Inspector General (OIG) review similarly found podiatrists' routine-foot-care claims frequently did not meet Medicare requirements.[11] Billing accuracy is both an operating cost and an audit/clawback risk.
• Fraud-and-abuse laws. The federal Anti-Kickback Statute, Physician Self-Referral (Stark) Law, and False Claims Act govern referrals, ownership, compensation, ancillary services, and Medicare/Medicaid billing.[31]
• Privacy and cybersecurity. The Health Insurance Portability and Accountability Act (HIPAA) requires covered providers and their business associates to protect protected health information (PHI).[30]
• Corporate-practice-of-medicine (CPOM) laws in many states restrict non-physician ownership or control of medical practices — the reason PE money enters through the MSO/MSA structure rather than owning the clinical entity outright, and a growing area of state legislative attention. The central diligence question is whether the structure preserves genuine physician control over clinical decisions.[32]

8. Competitive dynamics and consolidation

By the numbers, this is one of the least concentrated industries you will find. From the 2022 Economic Census:[3]

• Four largest firms = just 4.8% of receipts (four-firm concentration ratio, CR4).
• Top 8 / Top 20 / Top 50 = 7.0% / 11.5% / 17.6% of receipts.
• Herfindahl-Hirschman Index (HHI) = 11.1 (as reported) — effectively zero national concentration (antitrust regulators consider anything under 1,500 "unconcentrated").

Translation: no one owns this market. Roughly 6,500 firms split ~$5.4 billion, and even the fifty biggest players together hold under a fifth of it.[2][3] That fragmentation is the entire investment thesis on the private side — a long runway to buy small, disconnected practices and build regional scale.[20][21]

But competition is fundamentally local, and the low national ratios can understate local market power because patients usually choose among nearby providers. The strongest advantages are physician reputation and patient trust; referral relationships with primary-care doctors, hospitals, and diabetes and vascular providers; location and appointment availability; payer-network participation; surgical privileges and clinical breadth; DPM recruiting and retention; and efficient billing. Scale can improve purchasing, technology, compliance, marketing, and payer negotiations, and can support value-based contracts and ancillary services.

The consolidation wave. Private equity, having already rolled up dermatology, dentistry, gastroenterology, and orthopedics, has turned to podiatry as an "under-tracked" next segment.[20] Notable activity includes platform building by USFAS, Upperline Health, and Podiatry Growth Partners, with add-on acquisitions closing through 2024–2025.[20][21][22][24] The pitch to selling DPMs: relief from billing/compliance burden, better purchasing power, and a payday; the pitch to investors: buy at low single-practice multiples, integrate, and exit a larger, professionalized group at a higher multiple.

The main risk is integration — a platform can lose physicians, local referrals, and patient loyalty if centralized processes undermine clinical autonomy. And scrutiny is rising: a 2025 U.S. Government Accountability Office (GAO) report on physician-practice consolidation put the trend on policymakers' radar,[34] and in 2025 the Federal Trade Commission (FTC) reached a settlement over PE-backed consolidation in anesthesiology — not podiatry, but a signal that roll-up acquisitions, contracting, and investor control can draw antitrust attention.[33] Competition for the patient also comes from outside NAICS 621391: orthopedic foot-and-ankle surgeons (MDs/DOs under 621111), hospital outpatient departments, and retail/urgent-care substitutes for minor issues.[5]

9. Risks

• Reimbursement risk. Medicare, Medicare Advantage, Medicaid, and commercial payers can cut rates, narrow networks, or tighten coverage — including the routine-foot-care rules.[5][9][10]
• Documentation and clawback risk. With an ~11% improper-payment rate and active OIG attention, coding errors and unsupported routine-care claims carry recoupment, penalty, and exclusion exposure.[9][11]
• Payer-mix erosion. A shift toward Medicaid or Medicare Advantage (with tighter utilization management) compresses revenue per visit.[5][9]
• Physician dependence and labor scarcity. A practice may lean on one senior DPM or a narrow referral base; a small training pipeline (nine schools, ~18,000 practitioners), turnover, and owner succession all cap growth.[6][20]
• Demand leakage. Slow 2% projected job growth and substitution by primary-care and other clinicians limit volume upside.[5]
• Consolidation / integration risk (private side). Roll-ups depend on retaining producing DPMs, integrating disparate billing systems, and not overpaying; CPOM and antitrust scrutiny add legal complexity.[20][33][34]
• Corporate-practice risk. State law can invalidate or constrain ownership, compensation, or MSA provisions.[32]
• Clinical liability. Infection, poor wound healing, and surgical complications create legal and reputational exposure.
• Elective-volume and capital risk. Surgery, orthotics, and sports care can be deferred in downturns; ASCs, imaging, and labs need high utilization to justify fixed costs.
• Public-market opacity / supplier risk. Device, wound-care, payer, and enablement companies rarely break out podiatry as a segment, making attribution hard — and wound biologics and surgical devices face their own coverage and pricing pressure (e.g., skin-substitute reimbursement policy for names like Organogenesis).[15][16]

10. How to invest and the outlook

Public route. Because no listed company operates podiatry offices, public investors buy the adjacencies: bunion-surgery and foot/ankle implant makers (Stryker, Zimmer Biomet post-Paragon 28, Enovis, Treace), diabetic-wound biologics and dressings (Organogenesis, Integra, Smith+Nephew, ConvaTec), nerve-repair (Axogen), physician-enablement (Privia), and Medicare-heavy health plans (UnitedHealth, Humana, Elevance).[15][16][17][18][19][35][36][37][38][39][40][41] Each dependency differs: devices and implants track procedure volumes and product adoption; wound-care companies depend on clinical evidence, reimbursement, and coverage policy; health plans depend on medical-cost trends and provider-network economics; enablement companies depend on recruitment, retention, and risk-contract execution. These are bets on rising surgical volumes, diabetic-limb-preservation spending, and payer economics — not on the office business model itself — and each is diluted by non-podiatry lines. A foot-and-ankle product line is not necessarily a beneficiary of office-based podiatry revenue, and a health insurer may gain from utilization changes while pressuring provider reimbursement. Tickers, valuations, and dividends apply only here.

Private route (the direct one). Owning the industry means owning practices — as a DPM-owner, as an equity backer of an MSO platform (USFAS, Upperline Health, Podiatry Growth Partners, and others), or via co-investment, real estate, or lending around them.[20][21][22][24] The value-creation playbook is well-worn: acquire fragmented small practices at modest multiples, centralize billing/compliance and purchasing, grow ancillary (orthotics, DME, wound care) and surgical revenue, and exit a larger, de-risked group. When underwriting a practice or platform, focus on normalized owner compensation, same-clinic collections and visit trends, payer contracts and denial rates, DPM retention and succession, referral concentration, compliance history and audit exposure, ancillary economics, MSA terms and physician-control provisions, integration capability, and debt-service/exit assumptions. A platform's clinic count matters far less than organic collections, clinician productivity, retention, and cash conversion.

Near-term drivers to watch:

• The trajectory of diabetes prevalence and payer willingness to fund preventive foot care and limb-preservation programs — the largest structural tailwind.[13][15]
• Medicare policy on routine foot care, wound-biologic reimbursement, and documentation enforcement — the largest structural risk.[9][10][11]
• The pace and pricing of PE roll-ups, and whether early platforms exit successfully — the signal for whether this fragmented industry finally consolidates.[20][21][34]
• Value-based care models (e.g., Upperline's) that pay for keeping diabetic patients out of amputation — potentially a new, higher-margin revenue model if they scale.[25]

Bottom line: a small, unglamorous, deeply fragmented service industry with durable demographic demand, limited public-market access, and an active private-equity consolidation story that is still in its early innings. The best returns are likely to come from operational improvement, physician succession, better revenue-cycle management, and measurable diabetic-foot outcomes — not from rapid industry-wide volume growth.

---

Sources

1. U.S. Census Bureau. County Business Patterns (CBP), 2023 — NAICS 621391 Offices of Podiatrists (establishments, employment, annual and Q1 payroll). https://www.census.gov/programs-surveys/cbp/data/datasets.html
2. U.S. Census Bureau. 2022 Economic Census — All Sectors: Summary Statistics, NAICS 621391 (firms, receipts). https://data.census.gov/table/ECNBASIC2022.EC2200BASIC
3. U.S. Census Bureau. 2022 Economic Census — Concentration of Largest Firms, NAICS 621391 (CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
4. U.S. Small Business Administration. Table of Small Business Size Standards (NAICS 621391 = $9.0 million receipts). 2023. https://www.sba.gov/document/support-table-size-standards
5. U.S. Bureau of Labor Statistics. Occupational Outlook Handbook: Podiatrists (≈9,700 jobs; median wage $152,800, May 2024; 2% growth 2024–2034; demand drivers). https://www.bls.gov/ooh/healthcare/podiatrists.htm
6. American Association of Colleges of Podiatric Medicine (AACPM). Becoming a Podiatric Physician (DPM education, nine colleges, PMSR residency). https://aacpm.org/becoming-a-podiatric-physician/
7. American Podiatric Medical Association (APMA). What Is a Podiatrist? (scope of practice; ~18,000 podiatrists). https://www.apma.org/podiatristsfaq/
8. U.S. Census Bureau. 2022 NAICS Definition: 621391 Offices of Podiatrists. https://www.census.gov/naics/?details=621391&input=621391&year=2022
9. Centers for Medicare & Medicaid Services (CMS). Podiatry Care — Medicare Provider Compliance Tips (MLN) (routine-care rules; 11.2% improper-payment rate / $216.9M, 2024 FFS). https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/podiatry-care
10. CMS. Local Coverage Determination (LCD): Routine Foot Care (L35138) (routine-care exclusion, exceptions, Q7/Q8/Q9 modifiers, 60-day limit). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35138
11. HHS Office of Inspector General (OIG). Podiatrists' Claims for Routine Foot Care Services Did Not Comply With Medicare Requirements. 2025. https://oig.hhs.gov/reports/all/2025/podiatrists-claims-for-routine-foot-care-services-did-not-comply-with-medicare-requirements/
12. CMS. Medicare Coverage of Diabetes Supplies (therapeutic shoes/inserts benefit for qualifying diabetics). https://www.cms.gov/files/document/mln7674574-medicare-coverage-diabetes-supplies.pdf
13. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report (38.4M / 11.6% with diabetes). https://stacks.cdc.gov/view/cdc/148231/cdc_148231_DS1.pdf
14. U.S. Census Bureau. The Older Population: 2020 (55.8M age 65+, 16.8%). 2023. https://www.census.gov/library/publications/2023/decennial/c2020br-07.html
15. Market.us. Diabetic Foot Ulcer Treatment Market Size (North America ~$2.8B in 2024; amputation cost >$70,000). https://market.us/report/diabetic-foot-ulcer-treatment-market/
16. Organogenesis Holdings Inc. Investor Relations / advanced wound care and skin substitutes for diabetic foot ulcers (e.g., PuraPly randomized controlled trial results). https://investors.organogenesis.com/news-releases/news-release-details/organogenesis-achieves-primary-endpoint-randomized-controlled/
17. Treace Medical Concepts, Inc. Fourth Quarter and Full-Year 2024 Financial Results (SEC Form 8-K exhibit; ~$209M revenue, Lapiplasty). https://www.sec.gov/Archives/edgar/data/1630627/000095017024121456/tmci-ex99_1.htm
18. Zimmer Biomet. Completes Acquisition of Paragon 28 (April 2025). https://investor.zimmerbiomet.com/news-and-events/news/2025/04-21-2025-140129567
19. MD+DI. Zimmer Biomet Eyes Expansion into ~$5B Foot & Ankle Market with $1.2B Paragon 28 Acquisition. 2025. https://www.mddionline.com/orthopedic/zimmer-biomet-eyes-expansion-into-5b-foot-ankle-market-with-acquisition
20. KPMG Corporate Finance LLC. Podiatry Physician Practice M&A Industry Update (fragmentation, 96% ≤5 physicians, ~18,000 podiatrists, USFAS, PE backers). 2023. https://corporatefinance.kpmg.com/us/en/insights/2023/podiatry-physician-practice-ma.html
21. Podiatry Management. Private Equity-Backed Management Companies and Podiatry (MSO/MSA structure, platform activity). 2024. https://podiatrym.com/pdf/2024/10/HultmanFeature1024web.pdf
22. U.S. Foot & Ankle Specialists. Company site (80+ brands, 200+ locations, 22 states, 333+ doctors). https://us-fas.com/
23. NMS Capital. U.S. Foot & Ankle Specialists Expands Presence in the Mid-Atlantic. 2023. https://nms-capital.com/news/u-s-foot-ankle-specialists-expands-presence-with-acquisition-of-augusta-podiatric-medicine-surgery-and-center-for-foot-and-ankle-care-pc/
24. Businesswire / Upperline Health. Upperline Health Raises $58.35 Million to Fuel Specialty Value-Based Care. 2023. https://www.businesswire.com/news/home/20230607005219/en/Upperline-Health-Raises-%2458.35-Million-to-Fuel-Specialty-Value-Based-Care-Building-on-300-YOY-Growth
25. Silversmith Capital Partners. Upperline Health — Portfolio (podiatry/vascular/wound platform, value-based care). https://www.silversmith.com/portfolio/upperline-health
26. Compass Group Equity Partners. Podiatry Growth Partners Secures Funding. 2020. https://www.cgep.com/our-newest-platform-podiatry-growth-partners-secures-funding-while-also-landing-a-strategic-partnership-with-colorados-leading-podiatry-practice/
27. VSS Capital Partners. VSS Announces Investment in Podiatry Growth Partners. 2020. https://www.vss.com/news/vss-announces-investment-in-podiatry-growth-partners
28. Businesswire. Balance Health Joins Forces with Weil Foot & Ankle Institute. 2023. https://www.businesswire.com/news/home/20230605005822/en/Balance-Health-Joins-Forces-with-Weil-Foot-Ankle-Institute
29. Extremity Health Services. Comprehensive Podiatry Practice Management Services (Village Podiatry). https://www.extremityhealthservices.com/
30. U.S. Department of Health and Human Services. HIPAA — Covered Entities and Business Associates. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
31. HHS Office of Inspector General. Fraud & Abuse Laws (Anti-Kickback Statute, Stark Law, False Claims Act). https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
32. American Medical Association. State Momentum Grows to Curb Corporate Influence in Health Care (corporate practice of medicine). 2025. https://www.ama-assn.org/health-care-advocacy/state-advocacy/state-momentum-grows-curb-corporate-influence-health-care
33. Federal Trade Commission. FTC Secures Settlement with Private Equity Firm in Antitrust Roll-Up Scheme Case (anesthesiology). 2025. https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-secures-settlement-private-equity-firm-antitrust-roll-scheme-case
34. U.S. Government Accountability Office (GAO). Health Care Consolidation: Estimates of the Extent and Effects of Physician Consolidation (GAO-25-107450). 2025. https://files.gao.gov/reports/GAO-25-107450/index.html
35. Stryker. Foot and Ankle (product portfolio). https://www.stryker.com/us/en/portfolios/orthopaedics/foot-and-ankle.html
36. Enovis. Foot & Ankle (product portfolio). https://enovis.com/foot-and-ankle
37. UnitedHealth Group. 2024 Form 10-K. https://www.sec.gov/Archives/edgar/data/731766/000073176625000063/unh-20241231.htm
38. Privia Health Group. 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/1759655/000175965526000010/prva-20251231.htm
39. Humana. 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm
40. Elevance Health. 2025 Form 10-K. https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm
41. Axogen. 2025 Form 10-K. https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-26-000031/axgn-20251231.htm
42. U.S. Census Bureau. County Business Patterns: Coverage and Content (employer-only coverage; excludes most nonemployers and government employees). https://www.census.gov/econ/overview/mu0800.html
43. U.S. Census Bureau. 2022 Economic Census: Frequently Asked Questions (nonemployer exclusion from published reports). https://www.census.gov/programs-surveys/economic-census/year/2022/about/faq/faq-general.html